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Abstract
IMPORTANCE—The association between sickle cell trait (SCT) and chronic kidney disease 
(CKD) is uncertain.
OBJECTIVE—To describe the relationship between SCT and CKD and albuminuria in self-
identified African Americans.
DESIGN, SETTING, AND PARTICIPANTS—Using 5 large, prospective, US population-based 
studies (the Atherosclerosis Risk in Communities Study [ARIC, 1987–2013; n = 3402], Jackson 
Heart Study [JHS, 2000–2012; n = 2105], Coronary Artery Risk Development in Young Adults 
[CARDIA, 1985–2006; n = 848], Multi-Ethnic Study of Atherosclerosis [MESA, 2000–2012; n = 
1620], and Women’s Health Initiative [WHI, 1993–2012; n = 8000]), we evaluated 15 975 self-
identified African Americans (1248 participants with SCT [SCT carriers] and 14 727 participants 
without SCT [noncarriers]).
MAIN OUTCOMES AND MEASURES—Primary outcomes were CKD (defined as an 
estimated glomerular filtration rate [eGFR] of <60 mL/min/1.73 m2 at baseline or follow-up), 
incident CKD, albuminuria (defined as a spot urine albumin:creatinine ratio of >30 mg/g or 
albumin excretion rate >30 mg/24 hours), and decline in eGFR (defined as a decrease of >3 
mL/min/1.73 m2 per year). Effect sizes were calculated separately for each cohort and were 
subsequently meta-analyzed using a random-effects model.
RESULTS—A total of 2233 individuals (239 of 1247 SCT carriers [19.2%] vs 1994 of 14 722 
noncarriers [13.5%]) had CKD, 1298 (140 of 675 SCT carriers [20.7%] vs 1158 of 8481 
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noncarriers [13.7%]) experienced incident CKD, 1719 (150 of 665 SCT carriers [22.6%] vs 1569 
of 8249 noncarriers [19.0%]) experienced decline in eGFR, and 1322 (154 of 485 SCT carriers 
[31.8%] vs 1168 of 5947 noncarriers [19.6%]) had albuminuria during the study period. 
Individuals with SCT had an increased risk of CKD (odds ratio [OR], 1.57 [95% CI, 1.34–1.84]; 
absolute risk difference [ARD], 7.6% [95% CI, 4.7%–10.8%]), incident CKD (OR, 1.79 [95% CI, 
1.45–2.20]; ARD, 8.5% [95% CI, 5.1%–12.3%]), and decline in eGFR (OR, 1.32 [95% CI, 1.07–
1.61]; ARD, 6.1% [95% CI, 1.4%–13.0%]) compared with noncarriers. Sickle cell trait was also 
associated with albuminuria (OR, 1.86 [95% CI, 1.49–2.31]; ARD, 12.6% [95% CI, 7.7%–
17.7%]).
CONCLUSIONS AND RELEVANCE—Among African Americans in these cohorts, the 
presence of SCT was associated with an increased risk of CKD, decline in eGFR, and 
albuminuria, compared with noncarriers. These findings suggest that SCT may be associated with 
the higher risk of kidney disease in African Americans.
Sickle cell trait (SCT) is defined as inheritance of a single copy of the sickle mutation that 
results from a single base pair substitution in the gene encoding the β-globin chain of 
hemoglobin. It is estimated that SCT affects 1 in 12 African Americans and nearly 300 
million people worldwide.1,2
Renal disease in individuals with 2 copies of the sickle hemoglobin mutation (sickle cell 
disease) has been well characterized and includes impaired urinary concentrating ability, 
hematuria, chronic kidney disease (CKD), albuminuria, and end-stage renal disease 
(ESRD).3,4 Although SCT largely has been considered a benign condition, renal 
manifestations are the most commonly reported complications and include impaired urinary 
concentration, asymptomatic hematuria, and papillary necrosis.1,2,5,6 Nonetheless, the 
relationship of SCT to long-term functional impairment of the kidney has not been firmly 
established. Prior studies demonstrated a higher than expected prevalence of SCT among 
participants with ESRD, leading a National Institutes of Health (NIH) consensus panel to 
identify kidney disease as an area of priority in SCT research.1,7–9
African Americans have a disproportionately higher risk of CKD and progression to ESRD 
compared with white or Asian American populations.10–12 Sickle cell trait may be an 
important and unrecognized risk factor for renal disease in this population. We hypothesized 




All participants who were included in the analyses provided written informed consent for 
genetic studies, and institutional review board approval was obtained separately at each 
participating institution. The study population was derived from 5 population-based, 
prospective cohort studies from the United States: the Atherosclerosis Risk in Communities 
Study (ARIC), Jackson Heart Study (JHS), Coronary Artery Risk Development in Young 
Adults (CARDIA), Multi-Ethnic Study of Atherosclerosis (MESA), and Women’s Health 
Initiative (WHI). The design and methods of each study have been previously described13–17 
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and are summarized in Table 1 and described in the eAppendix in the Supplement. Clinical 
information was collected by self-report and in-person examination. Data from years 1987–
2013 were used for analysis in ARIC, 2000–2012 for JHS, 1985–2006 for CARDIA, 2000–
2012 for MESA, and 1993–2012 for WHI.
Exposure Assessment
Genotype data for rs334 encoding the sickle cell mutation (HBB p.Glu7Val) were obtained 
by custom genotyping or exome sequencing, or by imputation into the remaining sample of 
African Americans with genome-wide genotyping (eAppendix in the Supplement). We 
examined kidney function outcomes by the number of risk alleles (0 or 1).
Covariate Assessment
Baseline characteristics for each study participant were determined at the time of the first 
creatinine measurement. Hypertension was defined as a baseline systolic blood pressure 
measurement of 140 mm Hg or higher, a diastolic blood pressure measurement of 90 mm 
Hg or higher, or self-reported use of antihypertensive medication. Diabetes was defined as 
baseline fasting glucose measurement of 126 mg/dL or higher (to convert to mmol/L, 
multiply by 0.0555), self-reported physician diagnosis of diabetes, or self-reported use of 
oral hypoglycemic medication or insulin. To correct for any cryptic population structure, the 
global percentage of African ancestry for each participant was estimated based on high-
density genome-wide genotyping data using population genetics software programs 
(Structure or Frappe), as previously described.18,19 All participants included in this analysis 
had complete baseline data for age, sex, estimated African ancestry proportion, 
hypertension, and diabetes. The APOL1 risk variants (G1 and G2), which are associated 
with CKD in African Americans,20,21 were directly genotyped in all individuals in ARIC 
and a subset of participants in JHS.22
Kidney Function Outcome Assessment
Serum creatinine values were calibrated to the Cleveland Clinic or isotope dilution mass 
spectrometry reference standard. The eGFR was estimated from serum creatinine using the 
Chronic Kidney Disease Epidemiology Collaboration equation.23 The eGFR was also 
estimated using cystatin C measurements in available cohorts as described previously.24 
Chronic kidney disease was defined as an eGFR lower than 60 (stage G3 or higher in the 
Kidney Disease: Improving Global Outcomes [KDIGO] CKD definition)25 at any time 
during the study, including baseline or any follow-up visit. Incident CKD was defined as 
development of an eGFR lower than 60 mL/min/1.73 m2 during follow-up with a baseline 
eGFR of 60 mL/min/1.73 m2 or higher. Albuminuria was defined as spot urinary 
albumin:creatinine ratio (UACR) higher than 30 mg/g or an albumin excretion rate of more 
than 30 mg/24 hours (stage A2 or higher per KDIGO).25 Each cohort has been followed 
longitudinally; the number and frequency of repeated measures of serum creatinine, cystatin 
C, and UACR vary by cohort (Table 1). Participants with incident ESRD were identified in 
ARIC and WHI through linkage with the US Renal Data System, a national registry of all 
participants with ESRD.10
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The association of SCT carrier status with CKD outcomes was assessed using linear 
regression for quantitative eGFR and log-transformed urinary albumin, logistic regression 
for CKD, incident CKD, albuminuria, and presence of decline in kidney function (defined as 
a decrease in eGFR of >3 mL/min/1.73 m2 per year), and Cox regression for incident ESRD. 
To evaluate the association between SCT and eGFR decline, we used linear mixed models 
with random intercepts and slopes to estimate and compare linear trends in mean eGFR. 
Linear mixed models account for the correlation of observations within individual 
participants. Annual decline was estimated using eGFR data from examinations 1, 2, 4, and 
5 in ARIC; examinations 1, 4, 5, 6, and 7 in CARDIA; examinations 1, 3, 4, and 5 in 
MESA; examinations 1 and 3 in JHS; and examination 1 and a subsequent visit about 15 
years later in a subsample of WHI (n = 2139).
All regression models were minimally adjusted for covariates of age, sex, clinic or region, 
and African genetic ancestry to account for population stratification (model 1). We 
additionally adjusted for 2 major clinical risk factors: baseline diabetes and hypertension 
(model 2). All tests were 2-sided and a P value of less than .05 was considered statistically 
significant. The following sensitivity analyses were performed: (1) confining to ARIC and 
JHS, the 2 cohorts with the highest percentage of direct genotyping for rs334 (100% in 
ARIC; 98% in JHS; n = 5507) (eTable 2 in the Supplement), (2) excluding hemoglobin C 
carriers in genotyped samples, and (3) adjusting for the presence of 2 copies of the APOL1 
risk variants (G1 and G2) in individuals with available genotypic data (n = 4490).
Effect modification of SCT on the development of incident CKD by baseline hypertension 
or diabetes status or by the presence of 2 APOL1 risk variants was evaluated using 2 distinct 
methods: performing stratified analyses and including an interaction term in the original 
model. We defined the significance level for interaction as a P value of less than .05.
Because of the variability of risk across cohorts of various age ranges, we used ARIC 
prevalence and incidence rates as a fixed standard and calculated absolute risk differences 
from the meta-analyzed effect measures. Using ARIC as a standard allowed for the 
applicability of risk estimates to a middle-aged population.
Given the demographic heterogeneity of the cohorts included in this study, all data were 
analyzed separately within each cohort. Although the I2 for heterogeneity for all analyzed 
outcomes was less than 50%, with the I2 statistic being 0% for the primary outcomes, the 
cohort-specific results were meta-analyzed using a random-effects model to provide a 
conservative pooled estimate given the inherent heterogeneity in design and population 
between cohorts. Forest plots were generated for the primary outcomes. All statistical 
analyses were performed using Stata (StataCorp), version 12.
Results
Baseline Characteristics
After excluding participants with missing data for SCT (n = 9657), kidney phenotypes (n = 
241) or covariates (n = 891), and those with homozygous hemoglobin S (n = 8), the present 
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analysis included 15 975 African Americans from 5 population-based, prospective cohort 
studies (ARIC, JHS, CARDIA, MESA, and WHI). Genotype data for rs334 encoding the 
SCT mutation (HBB p.Glu7Val) were obtained by custom genotyping (n = 3402), exome 
sequencing (n = 2791), or by imputation into the remaining sample of African Americans 
with genomewide genotyping (n = 9782). The APOL1 risk variants (G1 and G2), which are 
associated with CKD in African Americans were directly genotyped in 3221 individuals in 
ARIC and a subset of 1269 participants in JHS. Baseline characteristics of African 
American participants by cohort and SCT carrier status are shown in Table 2. CARDIA 
participants were younger than participants of all other cohorts. A total of 1248 individuals 
in our study had SCT. The prevalence of SCT among the cohorts ranged from 6.4% to 9.3%, 
consistent with previous population prevalence estimates in African Americans.5,26,27 There 
was little difference in age, sex, body mass index (BMI, calculated as weight in kilograms 
divided by height in meters squared), hypertension, and diabetes between African American 
participants with SCT (SCT carriers) and without SCT (noncarriers) in each cohort.
Association of SCT With CKD and Incident CKD
Chronic kidney disease using creatinine values (eGFR <60 mL/min/1.73 m2) was present in 
2233 individuals (239 of 1247 SCT carriers [19.2%] vs 1994 of 14 722 noncarriers [13.5%]) 
in all 5 cohorts and in 1164 participants (113 of 516 SCT carriers [21.9%] vs 1051 of 6468 
noncarriers [16.2%]) from 4 cohorts based on cystatin C measurements. In the meta-
analysis, SCT carriers had an increased risk of CKD compared with noncarriers (odds ratio 
[OR], 1.57 [95% CI, 1.34–1.84]; absolute risk difference [ARD], 7.6% [95% CI, 4.7%–
10.8%]) (Figure 1). The meta-analyzed risk for CKD in the sensitivity analysis using ARIC 
and JHS alone was similar (82 of 381 SCT carriers [21.5%] vs 754 of 5126 noncarriers 
[14.7%]; OR, 1.69 [95% CI, 1.28–2.22]; ARD, 9.1% [95% CI, 3.9%–14.8%]) (eTable 2 in 
the Supplement). Similar results were also obtained using cystatin C–based eGFR (OR, 1.76 
[95% CI, 1.37–2.27]; ARD, 12.8% [95% CI, 6.8%–19.0%]) in the meta-analysis of available 
values from ARIC, JHS, CARDIA, and MESA (Table 3, model 2).
A total of 1298 (140 of 675 SCT carriers [20.7%] vs 1158 of 8481 noncarriers [13.7%]) 
experienced incident CKD. Incident CKD was more common in SCT carriers compared 
with non-carriers in all cohorts. (OR, 1.79 [95% CI, 1.45–2.20]; ARD, 8.5% [95% CI, 
5.1%–12.3%]) (Figure 2). Results were similar using data from ARIC and JHS alone (60 of 
325 SCT carriers [18.5%] vs 525 of 4506 noncarriers [11.7%]; OR, 1.81 [95% CI, 1.33–
2.45]; ARD, 8.7% [95% CI, 3.8%–14.4%]) (eTable 2 in the Supplement).
Association of SCT With Decline in eGFR and ESRD
Sickle cell trait was significantly associated with a faster decline in eGFR, with a pooled 
adjusted estimate of an increased rate of decline in eGFR of 0.218 mL/min/1.73 m2 per year 
(95% CI, 0.062 to 0.374) compared with noncarriers (Table 3, model 2). The rate of decline 
was 0.254 mL/min/1.73 m2 per year (95% CI, 0.089 to 0.418) faster for SCT carriers 
compared with noncarriers among the subgroup of 8923 individuals without baseline CKD. 
Sickle cell trait was not associated with faster decline in the subset of 361 participants with 
baseline eGFR lower than 60 mL/min/1.73 m2 (β = 0.024 [95% CI, −0.484 to 0.533])
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In our study, a total of 1719 individuals (150 of 665 SCT carriers [22.6%] vs 1569 of 8249 
noncarriers [19.0%]) from the 5 cohorts experienced eGFR decline. Evaluation of decline in 
eGFR (>3 mL/min/1.73 m2 decline per year) demonstrated that SCT carriers had an 
increased risk of decline compared with noncarriers in the meta-analysis (OR, 1.32 [95% CI, 
1.07 to 1.61]; ARD, 6.1% [95% CI, 1.4% to 13.0%]) (Figure 3). Using ARIC and JHS only, 
the results were similar (81 of 305 SCT carriers [26.6%] vs 1040 of 4272 noncarriers 
[24.3%]; OR, 1.21 [95% CI, 0.92 to 1.59]; ARD, 4.1% [95% CI, −1.7% to 10.5%]) (eTable 
2 in the Supplement). As with CKD and incident CKD, the direction of the association was 
consistent among all cohorts analyzed, though the relationship was not statistically 
significant in any individual cohort.
In the 2 cohorts with available US Renal Data System follow-up data on ESRD (ARIC and 
WHI), a total of 314 individuals (26 of 852 SCT carriers [3.1%] vs 288 of 10 411 
noncarriers [2.8%]) developed incident ESRD. Incidence of ESRD did not differ 
significantly between SCT carriers and noncarriers either in the individual cohorts or in 
meta-analysis (hazard ratio [HR], 1.02 [95% CI, 0.59 to 1.76]; ARD, 0.1% [95% CI, −1.8% 
to 3.3%]) (Table 3, model 2).
Association of SCT and Albuminuria
Using both UACR and albumin excretion rate data, the mean baseline urinary albumin was 
0.49 natural log units (95% CI, 0.351–0.628) of milligrams per gram or milligrams per 24 
hours higher among SCT carriers compared with noncarriers (Table 3, model 2). A total of 
1322 individuals (154 of 485 SCT carriers [31.8%] vs 1168 of 5947 noncarriers [19.6%]) 
from the 4 cohorts with available data had albuminuria. Similar to CKD, albuminuria (>30 
mg/g or >30 mg/24 hours) was more common in SCT carriers compared with noncarriers 
(OR, 1.86 [95% CI, 1.49–2.31; ARD, 12.6% [95% CI, 7.7%–17.7%]) in the pooled analysis 
(Figure 4). Similar results for albuminuria were observed using ARIC and JHS cohorts only 
(88 of 283 SCT carriers [31.1%] vs 801 of 3880 noncarriers [20.6%]; OR, 1.75 [95% CI, 
1.17–2.62]; ARD, 11.2% [95% CI, 2.9%–20.7%]) (eTable 2 in the Supplement).
Association of SCT and Incident CKD by Hypertension and Diabetes Status
There was no evidence that the association of SCT with incident CKD was modified by 
either baseline hypertension (P = .09) or diabetes status (P = .60) (Table 4).
Association of SCT and APOL1 Risk Variants on CKD and Albuminuria
We assessed the association of SCT and APOL1 on CKD and albuminuria in a subset of 
3221 participants in ARIC and 1269 participants in JHS with genotypes available for the G1 
and G2 alleles (eAppendix in the Supplement). Carrier status for SCT and APOL1 risk 
genotypes segregated independently, with 22 individuals (1%) carrying both genetic risk 
factors in ARIC and 11 individuals (1%) in JHS. There was no significant genetic 
interaction by APOL1 status on the relationship of SCT and CKD (P = .17) or albuminuria 
(P = .18) (Table 5).
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Although SCT is known to be associated with hematuria and renal papillary necrosis,1,2,5 
the relationship between SCT and CKD has not been clearly established. In this pooled 
analysis of more than 15 000 individuals from 5 population-based cohorts of African 
Americans, SCT was associated with an increased risk of CKD and incident CKD, decline 
in eGFR, and albuminuria. Our results were reproducible within each individual cohort. Our 
findings show an association of SCT with the development of CKD in African Americans.
Potential pathophysiological mechanisms for kidney injury in individuals with sickle cell 
disease have been described. Chronic reversible sickling induced by hypoxia in the renal 
medulla results in ischemia and microinfarction of the renal tubules.6 Local ischemia and 
hemolysis cause release of vasoactive factors,28 which promotes glomerular hyperfiltration, 
ultimately resulting in glomerulosclerosis and proteinuria.29 In SCT, injection radiographs 
demonstrate renal medullary vascular disruption, though to a lesser extent than seen in sickle 
cell disease, suggesting that sickle hemoglobin may have a dose-dependent relationship with 
kidney injury.6 Our finding that SCT was related to both CKD and albuminuria is consistent 
with these proposed mechanisms.
In our study, the association of SCT with CKD appeared to be independent of APOL1 risk 
variants, which have recently drawn attention as an explanation for the higher risk of CKD 
in African Americans.20,21 Although APOL1 risk variants are associated with CKD 
progression in African Americans, they do not fully explain the observed increased risk of 
CKD among African Americans compared with other populations.20 Our findings suggest 
that SCT may additionally relate to the racial disparity in CKD, with a population 
attributable risk for incident CKD of approximately 6%. Although we observed no gene-
gene interaction with APOL1 or gene-environment interaction with diabetes or hypertension, 
further studies with even larger sample sizes are needed to sufficiently address potential 
interactions between SCT and these other CKD risk factors.
In contrast to APOL1, genetic testing for SCT is performed widely in the United States. 
Universal newborn screening for sickle hemoglobin is mandated in all 50 states, and 
screening for SCT is also variably implemented in college athletics, pregnancy, and renal 
transplant donor evaluations.1,7,30 As a result, SCT carriers are identified at a young age, 
and high-risk individuals may benefit from early intervention. Studies investigating 
angiotensin-converting enzyme inhibition to delay the progression of albuminuria in 
participants with sickle cell disease and sickle nephropathy have had promising results,31 
although the long-term benefits remain unknown. Angiotensin-converting enzyme inhibition 
in SCT-associated CKD may provide a similar potential benefit but has not been evaluated.
Our study has limitations. The clinical and pathological cause of CKD in each individual 
was not explicitly recorded. In addition, direct genotyping for SCT was not available on all 
individuals; however, sensitivity analysis using the cohorts with the highest percentage of 
direct genotyping yielded substantially similar results to the overall meta-analysis. We were 
also unable to evaluate the modifying effects of coexisting hemoglobin mutations, such as a-
thalassemia.32 Our ability to assess the potential for interaction of APOL1 was limited 
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because genotypic data were only available in 2 cohorts. The strengths of our study include 
the large prospective, population-based sample of African Americans with detailed 
genotypic and phenotypic information and the reproducibility of results across cohorts with 
differing geographic, age, and sex compositions. In addition, we were able to evaluate 
outcomes that have not been previously evaluated in SCT, including CKD, decline in eGFR, 
and albuminuria.
Sickle cell trait was not associated with ESRD in our analysis. Our study is, to our 
knowledge, the first prospective study of SCT and ESRD; however, the relatively small 
number of incident ESRD cases, which was available by US Renal Data System linkage in 
only 2 cohorts, may have resulted in insufficient power to detect an association with SCT. 
Two prior studies examining the relationship between SCT and ESRD have demonstrated 
discordant findings, which can be potentially explained by limitations and variation in 
design.9,33 A single-center study demonstrated a higher prevalence of SCT compared with 
the population prevalence obtained from birth records.9 Another study, a cross-sectional 
analysis of a preexisting genetic cohort, did not show a higher prevalence of SCT among 
participants with ESRD compared with nonnephropathy controls.33 Although we were 
unable to demonstrate a clear association with ESRD, the observed relationship with eGFR 
decline suggests that SCT may be associated with severe renal phenotypes. Additional 
prospective studies are needed to resolve this question.
In this large multicohort study, SCT was associated with CKD and incident CKD, decline in 
eGFR, and albuminuria in African Americans. These associations were independent of 
APOL1 risk variants and may offer an additional genetic explanation for the increased risk 
of CKD observed among African Americans compared with other racial groups. Our study 
also highlights the need for further research into the renal complications of SCT. Because 
screening for SCT is already being widely performed, accurate characterization of disease 
associations with SCT is critical to inform policy and treatment recommendations.
Conclusions
Among African Americans in these cohorts, the presence of SCT was associated with an 
increased risk of CKD, decline in eGFR, and albuminuria, compared with noncarriers. These 
findings suggest that SCT may be related to the higher risk of kidney disease in African 
Americans.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Meta-analysis of Odds Ratios for CKD Using Creatinine Values Comparing Sickle Cell 
Trait Carriers With Noncarriers
CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate; SCT, 
sickle cell trait. Chronic kidney disease was defined as an eGFR level lower than 60 
mL/min/1.73 m2 at baseline or follow-up. All models adjusted for age, sex, clinic or region, 
African genetic ancestry, hypertension, and diabetes. The size of data markers indicate the 
weight of study.
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Figure 2. Meta-analysis of Odds Ratios for Incident CKD Using Creatinine Values Comparing 
Sickle Cell Trait Carriers With Noncarriers
CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate; SCT, 
sickle cell trait. Incident CKD was defined as development of an eGFR level lower than 60 
mL/min/1.73 m2 during follow-up. All models adjusted for age, sex, clinic or region, 
African genetic ancestry, hypertension, and diabetes. The size of data markers indicate the 
weight of study.
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Figure 3. Meta-analysis of Odds Ratios for Estimated Glomerular Filtration Rate Decline 
Comparing Sickle Cell Trait Carriers With Noncarriers
CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate; SCT, 
sickle cell trait. Estimated glomerular filtration rate decline was defined as a decrease in 
eGFR level of more than 3 mL/min/1.73 m2 per year. All models adjusted for age, sex, 
clinic or region, African genetic ancestry, hypertension, and diabetes. The size of data 
markers indicate the weight of study.
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Figure 4. Meta-analysis of Odds Ratios for Albuminuria Comparing Sickle Cell Trait Carriers 
With Noncarriers
CKD indicates chronic kidney disease; SCT, sickle cell trait. Albuminuria was defined as 
spot urine albumin:creatinine ratio higher than 30 mg/g or albumin excretion rate higher 
than 30 mg/24 hours. All models adjusted for age, sex, clinic or region, African genetic 
ancestry, hypertension, and diabetes. The size of data markers indicate the weight of study.
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